Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 14/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5150263 | 0.85 | NR1H2 (0.46) | NR1H2NR1H3RXRA | |
| SCHEMBL6209025 | 0.81 | NR1H2 (0.41) | NR1H2NR1H3 | |
| SCHEMBL5153251 | 0.80 | HTR4 (0.46) | NR1H2NR1H3 | |
| SCHEMBL5153357 | 0.77 | PDE4B (0.44) | NR1H2NR1H3 | |
| SCHEMBL5153880 | 0.77 | PDE4B (0.44) | NR1H2NR1H3RXRA | |
| SCHEMBL6542920 | 0.77 | PDE4B (0.40) | NR1H2NR1H3RXRA | |
| SCHEMBL5150005 | 0.76 | PDE4B (0.44) | NR1H2NR1H3RXRA | |
| SCHEMBL5153201 | 0.76 | PDE4B (0.44) | NR1H2NR1H3RXRA | |
| SCHEMBL30476477 | 0.75 | ACACB (0.44) | L3MBTL1NR1H2NR1H3ACACB | |
| SCHEMBL5152402 | 0.75 | POLB (0.46) | L3MBTL1NR1H2NR1H3ACACBKAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | L3MBTL1 703/4885NR1H2 2538/4885NR1H3 2098/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | L3MBTL1 503/4885NR1H2 2668/4885NR1H3 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.